Table of Contents
| << Previous Issue | Mar 2012 (Vol: 2012, Issue: 3) | Next Issue >> |
- Section: Distribution & Marketing
-
Actelion Gains Rights to Auxilium’s Xiaflex® in Canada, Australia, Brazil and Mexico
-
Novartis’ Alcon Gains ex-US Rights to ThromboGenics’ Ocriplasmin
- Section: Joint Venture
-
Daiichi Sankyo and GSK to Establish Vaccines Joint Venture in Japan
- Section: Licensing
-
Galapagos Lands US$1.35 B Deal with Abbott for Phase II JAK Inhibitor
-
Avanir Licenses Concert’s Deuterium-Modified Dextromethorphan Products in Potential US$200 M Deal
- Section: Mergers & Acquisitions
-
Dainippon Sumitomo Pharma Expands its Oncology Presence with Boston Biomedical Acquisition
-
Shire Bolsters its Haematology Business with US$325 M FerroKin BioSciences Acquisition
-
GSK Finds a Buyer in Omega Pharma for its Non-Core OTC Brands in Europe
-
Sanofi Augments its Biosurgery Unit with Pluromed Acquisition
-
NicOx Targets Ophthalmology with Altacor Buyout Option
- Section: Research & Development
-
Angiochem Validates its EPiC Technology via Rare Disease Deal with GSK
-
Shire Collaborates with arGEN-X to Discover and Develop Antibody Products for Rare Diseases
-
Mersana Therapeutics Raises Profile with Antibody-Drug Conjugate Collaboration with Endo
-
Medicago and Mitsubishi Tanabe Pharma Form Vaccines Alliance
RSS